AMLX
Amylyx Pharmaceuticals, Inc.
12.93
USD
This page is just a preview of the data found in TrendSpider’s full version
Amylyx Pharmaceuticals, Inc. stock is down -17.96% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 1 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 3 CALLs, 7 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 14 Nov 18:51 | 19 Jan, 2024 | 12.50 | 1179 | ||
| 14 Nov 20:45 | 17 Nov, 2023 | 20.00 | 1917 | ||
| 15 Nov 16:02 | 17 Nov, 2023 | 20.00 | 1888 | ||
| 15 Nov 16:02 | 17 Nov, 2023 | 20.00 | 1888 | ||
| 15 Nov 19:51 | 17 Nov, 2023 | 20.00 | 1888 | ||
| 16 Nov 20:39 | 19 Jan, 2024 | 17.50 | 800 | ||
| 17 Nov 14:41 | 17 Nov, 2023 | 20.00 | 1888 | ||
| 17 Nov 14:50 | 17 Nov, 2023 | 20.00 | 1888 | ||
| 20 Nov 16:26 | 15 Mar, 2024 | 20.00 | 50 | ||
| 21 Nov 19:27 | 15 Mar, 2024 | 17.50 | 8 |
Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.
